Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Anus Neoplasms 2Rectal Neoplasms 1HIV Infections 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Anal Canal Carcinoma 1Adenomatous Polyposis Coli 1

Interventions

Fluorouracil 67Leucovorin 61Oxaliplatin 49Irinotecan 31Capecitabine 23Cetuximab 22Bevacizumab 20Folfox protocol 13Radiotherapy 12Chemotherapy, Adjuvant 11Neoadjuvant Therapy 10Erlotinib Hydrochloride 7dehydroftorafur 5Trastuzumab 5Radiation 5Melphalan 5Magnetic Resonance Spectroscopy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5sargramostim 4Sigmoidoscopy 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Gene Expression Profiling 4Gefitinib 4Floxuridine 4Biopsy 4aldesleukin 3Sorafenib 3Semaxinib 3Polymerase Chain Reaction 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rectal Neoplasms × Colonoscopy × Clear all
NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡